GIP3

GIP3 is a novel triple hormone receptor agonist research compound that simultaneously activates GIP, glucagon, and incretin receptors. This tri-agonist approach represents the next evolution in incretin-based pharmacology research, building on dual agonism by incorporating glucagon receptor activity. In preclinical studies in rodent models, glucagon receptor agonism has been associated with increased energy-expenditure parameters, hepatic lipid-oxidation markers, and thermogenesis-related readouts, while the GIP and incretin components modulate appetite-behavior and glycemic parameters in preclinical metabolic-parameter studies in rodent models.

The glucagon receptor component of this tri-agonist's activity profile is of particular scientific interest. Glucagon receptor agonism promotes hepatic glycogenolysis and gluconeogenesis, which under normal circumstances would elevate blood glucose. However, the concurrent GIP and incretin receptor agonism appears to counterbalance this hyperglycemic potential in preclinical systems while allowing the metabolic signaling effects of glucagon, including energy-expenditure parameters, lipolysis markers, and amino-acid catabolism, to be studied in research models.

Preclinical studies in rodent models have demonstrated that rationally designed triple agonist peptides produce distinct preclinical metabolic-parameter profiles compared to dual or single agonists, including shifts in body-composition parameters, glucose-tolerance markers, and hepatic steatosis readouts in animal research models. These findings have generated substantial research interest in tri-agonism as a preclinical pharmacology research strategy.